Document:

EX-10.2(ii)

 Exhibit 10.2(ii) 

FIBROGEN, INC. 
 1999
STOCK PLAN 
 INCENTIVE STOCK OPTION AGREEMENT 
  

	 	(A)	Name of Optionee: 

	 	(B)	Grant Date: 

	 	(C)	Number of Shares: 

	 	(D)	Exercise Price: 

	 	(E)	Vesting Base Date: 

	 	(F)	Effective Date: 

	 	(G)	Option Number: 

 THIS INCENTIVE STOCK OPTION AGREEMENT (the “Agreement”), is made and
entered into as of the date set forth in Item F above (the “Effective Date”) between FibroGen, Inc., a Delaware corporation (the “Company”) and the person named in Item A above (“Optionee”). 

THE PARTIES AGREE AS FOLLOWS: 

1. Grant of Option; Vesting Base Date. 

1.1 Grant. The Company hereby grants to Optionee pursuant to the Company’s 1999 Stock Plan (the “Plan”), a copy of which
is attached to this Agreement as Exhibit 1, an incentive stock option (the “ISO”) to purchase all or any part of an aggregate of the number of shares (the “ISO Shares”) of the Company’s Common Stock (as defined in the Plan)
listed in Item C above on the terms and conditions set forth herein and in the Plan, the terms and conditions of the Plan being hereby incorporated into this Agreement by reference. Pursuant to Section 6.3.4. of the Plan, in the event that ISOs
granted to Optionee under all incentive stock option plans of the Company and its subsidiaries and this ISO in the aggregate would “vest” (or become exercisable for the first time by any Optionee for purposes of this calculation) in excess
of the $100,000 fair market value limit in a calendar year, this ISO or such other ISO (according to the order of the most recent grant in conformity with Section 422(d) of the Internal Revenue Code and to the extent permitted under the terms
of such other ISOs) to the extent or portions thereof that exceed such limit shall be treated as nonstatutory stock options. 
 1.2
Vesting Base Date. The parties hereby establish the date set forth in Item E above as the Vesting Base Date (as defined in Section 5.1 below). 

 2. Exercise Price. The exercise price for purchase of each share of Common Stock covered
by this ISO shall be the price set forth in Item D above. 
 3. Term. Unless otherwise specified on Exhibit 3 attached hereto, if any
(the absence of such exhibit indicating that no such exhibit was intended), this ISO shall expire as provided in Section 6.1.12 of the Plan. 

4. Adjustment of ISOs. The Company shall adjust the number and kind of shares and the exercise price thereof in certain circumstances
in accordance with the provisions of Section 6.1.1 of the Plan. 
 5. Exercise of Options. 

5.1 Vesting Time of Exercise. This ISO shall be exercisable according to the schedule set forth on Exhibit 5.1 attached hereto. Such
schedule shall commence as of the date set forth in Item (E) above (the “Vesting Base Date”). Notwithstanding the foregoing, at the sole discretion of the Administrator of the Plan (as defined in Section 4 thereof), prior to the
vesting of the ISO, the Administrator may allow Optionee on a case by case basis to exercise any unvested portion of the ISO subject to the Company’s right of repurchase that shall lapse in accordance with the same schedule as set forth on
Exhibit 5.1. 
 5.2 Exercise After Termination of Status as an Employee, Director or Consultant. In the event of termination of
Optionee’s continuous status as an employee, director or consultant, this ISO may be exercised only in accordance with the provisions of Section 6.1.7 of the Plan. 

5.3 Manner of Exercise. Optionee may exercise this ISO, or any portion of this ISO, by giving written notice to the Company at its
principal executive office, to the attention of the officer of the Company designated by the Plan Administrator, accompanied by a copy of a Notice of Exercise 1999 in substantially the form attached hereto as Exhibit 5.3 executed by Optionee
(or at the option of the Company such other form of stock purchase agreement as shall then be acceptable to the Company), payment of the exercise price and payment of any applicable withholding or employment taxes. The date the Company receives
written notice of an exercise hereunder accompanied by payment will be considered as the date this ISO was exercised. 
 5.4 Payment.
Payment may be made for ISO Shares purchased at the time written notice of exercise of the ISO is given to the Company, by delivery of cash, check, or previously owned shares of Common Stock (provided that delivery of previously owned shares may not
be made more than once in any six-month period. In addition, at the sole discretion of the Administrator of the Plan, on a case by case basis, payment for a portion of the exercise price may be permitted with delivery of a full recourse promissory
note on such terms as may be deemed appropriate by the Administrator. The proceeds of any payment shall constitute general funds of the Company. 

  
 -2- 

 5.5 Delivery of Certificate. Promptly after receipt of written notice of exercise of the
ISO, the Company shall, without stock issue or transfer taxes to the Optionee or other person entitled to exercise, deliver to the Optionee or other person a certificate or certificates for the requisite number of ISO Shares. An Optionee or
transferee of an Optionee shall not have any privileges as a shareholder with respect to any ISO Shares covered by the option until the date of issuance of a stock certificate. 

6. Nonassignability of ISO. This ISO is not assignable or transferable by Optionee except by will or by the laws of descent and
distribution. During the life of Optionee, the ISO is exercisable only by the Optionee. Any attempt to assign, pledge, transfer, hypothecate or otherwise dispose of this ISO in a manner not herein permitted, and any levy of execution, attachment, or
similar process on this ISO, shall be null and void. 
 7. Company’ s Repurchase Rights. The ISO Shares arising from exercise of
this ISO shall be subject to a right of repurchase in favor of the Company (the “Right of Repurchase”) to the extent set forth on Exhibit 7 attached hereto (the absence of such exhibit indicating that no such exhibit was intended and that
the ISO shall be subject to the limitations set forth on Exhibit 5.1). If the Optionee’s employment with the Company terminates before the Right of Repurchase lapses in accordance with Exhibit 7, the Company may purchase ISO Shares subject to
the Right of Repurchase (either by payment of cash or by cancellation of purchase money indebtedness) for an amount equal to the price the Optionee paid for such ISO Shares (exclusive of any taxes paid upon acquisition of the stock) by giving notice
at any time within the later of (a) 30 days after the acquisition of the ISO Shares upon option exercise, or (b) 90 days after such termination of employment that the Company is exercising its right of repurchase. The Company shall include
with such notice payment in full in cash or by evidence of cancellation of purchase money indebtedness. The Optionee may not dispose of or transfer ISO Shares while such shares are subject to the Right of Repurchase and any such attempted transfer
shall be null and void. 
 8. Company’s Right of First Refusal. 

8.1 Right of First Refusal. In the event that the Optionee proposes to sell, pledge, or otherwise transfer any ISO Shares or any
interest in such shares to any person or entity, the Company shall have a right of first refusal (the “Right of First Refusal”) with respect to such ISO Shares. If Optionee desires to transfer ISO Shares, Optionee shall give a written
notice (the “Transfer Notice”) to the Company describing fully the proposed transfer, including the number of ISO Shares proposed to be transferred, the proposed transfer price, and the name and address of the proposed transferee. The
Transfer Notice shall be signed both by Optionee and by the proposed transferee and must constitute a binding commitment of both such parties for the transfer of such ISO Shares. The Company may elect to purchase all, but not less than all, of the
ISO Shares subject to the Transfer Notice by delivery of a notice of exercise of the Company’s Right of First Refusal within 30 days after the date the Transfer Notice is delivered to the Company. The purchase price paid by the Company shall be
the price per share equal to the 

  
 -3- 

 
proposed per share transfer price, and shall be paid to the Optionee within 60 days after the date the Transfer Notice is received by the Company, unless a longer period for payment was offered
by the proposed transferee, in which case the Company shall pay the purchase price within such longer period. The Company’s rights under this Section 8.1 shall be freely assignable, in whole or in part. Notwithstanding the foregoing, the
Right of First Refusal does not apply to a transfer of shares by gift or devise to the Optionee’s immediate family (i.e., parents, spouse or children or to a trust for the benefit of the Optionee or any of the Optionee’s immediate family
members), but does apply to any subsequent transfer of such shares by such immediate family members. 
 8.2 Transfer of ISO Shares.
If the Company fails to exercise the Right of First Refusal within 30 days after the date the Transfer Notice is delivered to the Company, the Optionee may, not later than 75 days following delivery to the Company of the Transfer Notice, conclude a
transfer of the ISO Shares subject to the Transfer Notice on the terms and conditions described in the Transfer Notice. Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent
proposed transfer by the Optionee, shall again be subject to the Right of First Refusal and shall require compliance by the Optionee with the procedure described in Section 8.1 of this Agreement. If the Company exercises the Right of First
Refusal, the parties shall consummate the sale of ISO shares on the terms, other than price, as applicable under Section 8.1, set forth in the Transfer Notice; provided, however, in the event the Transfer Notice provides for payment for the ISO
Shares other than in cash, the Company shall have the option of paying for the ISO Shares by paying in cash the present value of the consideration described in the Transfer Notice; and further provided that if the value of noncash consideration is
to be paid, the Optionee disagrees with the value determined by the Company, the Optionee may request an independent appraisal by an appraiser acceptable to the Optionee and the Company, the costs of such appraisal to be borne equally by the
Optionee and the Company. 
 8.3 Binding Effect. The Right of First Refusal shall inure to the benefit of the successors and assigns
of the Company and shall be binding upon any transferee of ISO Shares other than a transferee acquiring ISO Shares in a transaction where the Company failed to exercise the Right of First Refusal (a “Free Transferee”) or a transferee of a
Free Transferee. 
 8.4 Termination of Company’s Right of First Refusal. Notwithstanding anything in this Section 8, the
Company shall have no Right of First Refusal, and Optionee shall have no obligation to comply with the procedures in Sections 8.1 through 8.3 after the earlier of (i) the closing of the Company’s initial public offering to the public
generally, or (ii) the date ten (10) years after the Effective Date. 
 9. Market Standoff. Optionee hereby agrees that if
so requested by the Company or any representative of the underwriters in connection with any registration of the offering of the securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”), Optionee shall
not sell or otherwise transfer the ISO Shares for a period of 90 days following the effective date of a Registration Statement filed the Securities Act; provided that such restrictions shall only apply to the first two registration statements of the
Company to become effective under the Securities Act which include securities to be sold on behalf of the 

  
 -4- 

 
Company in an underwritten public offering under the Securities Act. The Company may impose stop-transfer instructions with respect to the ISO Shares subject to the foregoing restrictions until
the end of each such 90-day period. 
 10. Restriction on Issuance of Shares. 

10.1 Legality of Issuance. The Company shall not be obligated to sell or issue any ISO Shares pursuant to this Agreement if such sale
or issuance, in the opinion of the Company and the Company’s counsel, might constitute a violation by the Company of any provision of law, including without limitation the provisions of the Securities Act. 

10.2 Registration or Qualification of Securities. The Company may, but shall not be required to, register or qualify the sale of this
ISO or any ISO Shares under the Securities Act or any other applicable law. The Company shall not be obligated to take any affirmative action in order to cause the grant or exercise of this option or the issuance or sale of any ISO Shares pursuant
thereto to comply with any law. 
 11. Restriction on Transfer. Regardless whether the sale of the ISO Shares has been registered
under the Securities Act or has been registered or qualified under the securities laws of any state, the Company may impose restrictions upon the sale, pledge or other transfer of ISO Shares (including the placement of appropriate legends on stock
certificates) if, in the judgment of the Company and the Company’s counsel, such restrictions are necessary or desirable in order to achieve compliance with the provisions of the Securities Act, the securities laws of any state, or any other
law, or if the Company does not desire to have a trading market develop for its securities. 
 12. Stock Certificate. Stock
certificates evidencing ISO Shares may bear such restrictive legends as the Company and the Company’s counsel deem necessary or advisable under applicable law or pursuant to this Agreement. 

13. Disqualifying Dispositions. If stock acquired by exercise of this ISO is disposed of within two years after the Effective Date or
within one year after date of such exercise (as determined under Section 5.3 of this Agreement), the Optionee immediately prior to the disposition shall promptly notify the Company in writing of the date and terms of the disposition and shall
provide such other information regarding the disposition as the Company may reasonably require. 
 14. Representations, Warranties,
Covenants, and Acknowledgments of Optionee Upon Exercise of ISO. Optionee hereby agrees that in the event that the Company and the Company’s counsel deem it necessary or advisable in the exercise of their discretion, the issuance of ISO
Shares may be conditioned upon certain representations, warranties, and acknowledgments by the person exercising the ISO (the “Purchaser”), including, without limitation, those set forth in Sections 14.1 through 14.8 inclusive: 

  
 -5- 

 14.1 Investment. Purchaser is acquiring the NQ Shares for Purchaser’s own account,
and not for the account of any other person. Purchaser is acquiring the ISO Shares for investment arid not with a view to distribution or resale thereof except in compliance with applicable laws regulating securities. 

14.2 Business Experience. Purchaser is capable of evaluating the merits and risks of Purchaser’s investment in the Company
evidenced by purchase of the ISO Shares. 
 14.3 Relation to Company. Purchaser is presently an officer, director, or other employee
of, or consultant to the Company, and in such capacity has become personally familiar with the business, affairs, financial condition, and results of operations of the Company. 

14.4 Access to Information. Purchaser has had the opportunity to ask questions of, and to receive answers from, appropriate executive
officers of the Company with respect to the terms and conditions of the transaction contemplated hereby and with respect to the business, affairs, financial condition, and results of operations of the Company. Purchaser has had access to such
financial and other information as is necessary in order for Purchaser to make a fully-informed decision as to investment in the Company by way of purchase of the ISO Shares, and has had the opportunity to obtain any additional information necessary
to verify any of such information to which Purchaser has had access. 
 14.5 Speculative Investment. Purchaser’s investment in
the Company represented by the ISO Shares is highly speculative in nature and is subject to a high degree of risk of loss in whole or in part. The amount of such investment is within Purchaser’s risk capital means and is not so great in
relation to Purchaser’s total financial resources as would jeopardize the personal financial needs of Purchaser or Purchaser’s family in the event such investment were lost in whole or in part. 

14.6 Registration. Purchaser must bear the economic risk of investment for an indefinite period of time because the sale to Purchaser
of the ISO Shares has not been registered under the Securities Act and the ISO Shares cannot be transferred by Purchaser unless such transfer is registered under the Securities Act or an exemption from such registration is available. The Company has
made no agreements, covenants, or undertakings whatsoever to register the transfer of any of the NQ Shares under the Securities Act. The Company has made no representations, warranties, or covenants whatsoever as to whether any exemption from the
Securities Act, including without limitation any exemption for limited sales in routine brokers’ transactions pursuant to Rule 144, will be available; if the exemption under Rule 144 is available at all, it may not be available until at least
one year after payment of cash for the ISO Shares and not then unless: (i) a public trading market then exists in the Company’s common stock; (ii) adequate information as to the Company’s financial and other affairs and
operations is then available to the public; and (iii) all other terms and conditions of Rule 144 have been satisfied. Purchaser understands that the resale provisions of Rule 701 will not apply until 90 days after the Company becomes subject to
the reporting obligations of the Securities Exchange Act of 1934 (typically 90 days after the effective date of an initial public offering). 

  
 -6- 

 14.7 Public Trading. None of the Company’s securities is presently publicly traded,
and the Company has made no representation, covenant, or agreement as to whether there will be a public market for any of its securities. 

14.8 Tax Advice. The Company has made no warranties or representations to Purchaser with respect to the income tax consequences of the
transactions contemplated by the agreement pursuant to which the ISO Shares will be purchased and Purchaser is in no manner relying on the Company or its representatives for an assessment of such tax consequences. 

15. Assignment; Binding Effect. Subject to the limitations set forth in this Agreement, this Agreement shall be binding upon and inure
to the benefit of the executors, administrators, heirs, legal representatives, and successors of the parties hereto; provided, however, that Optionee may not assign any of Optionee’s rights under this Agreement. 

16. Damages. Optionee shall be liable to the Company for all costs and damages, including incidental and consequential damages,
resulting from disposition of ISO Shares which is not in conformity with the provisions of this Agreement. 
 17. Governing Law. This
Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware excluding those laws that direct the application of the laws of another jurisdiction. 

18. Notices. All notices and other communications under this Agreement shall be in writing. Unless and until the Optionee is notified
in writing to the contrary, all notices, communications, and documents directed to the Company and related to the Agreement, if not delivered by hand, shall be mailed, addressed as follows: 

FibroGen, Inc. 
 225 Gateway
Boulevard 
 South San Francisco, California 94080 

Attention: Dorothy Pacini 
 Unless and until the
Company is notified in writing to the contrary, all notices, communications, and documents intended for the Optionee and related to this Agreement, if not delivered by hand, shall be mailed to Optionee’s last known address as shown on the
Company’s books. Notices and communications shall be mailed by first class mail, postage prepaid; documents shall be mailed by registered mail, return receipt requested, postage prepaid. All mailings and deliveries related to this Agreement
shall be deemed received when actually received, if by hand delivery, and two business days after mailing, if by mail. 

  
 -7- 

 IN WITNESS WHEREOF, the parties have executed this Incentive Stock Option Agreement as of the Effective Date.

  

			
	FibroGen, Inc.
		
	By:	 	  

		
	Title	 	  

 The Optionee hereby accepts and agrees to be bound by all of the terms and conditions of this Agreement and the Plan.

  

			
	  

	Optionee
		
	Dated:	 	  

 Optionee’s spouse indicates by the execution of this Incentive Stock Option Agreement his or her consent to be
bound by the terms thereof as to his or her interests, whether as community property or otherwise, if any, in the option granted hereunder, and in any ISO Shares purchased pursuant to this Agreement. 

 

	
	  

	Optionee’s Spouse

  
 -8- 

 EXHIBITS 
  

			
	Exhibit 1	  	1999 Stock Plan
		
	Exhibit 3	  	Expiration of Incentive Stock Option (if applicable)
		
	Exhibit 5.1	  	Time of Exercise
		
	Exhibit 5.3	  	Notice of Exercise 1999
		
	Exhibit 7	  	Right of Repurchase (if applicable)

 AMENDED AND RESTATED 

1999 STOCK PLAN 
 OF 

FIBROGEN, INC. 

 EXHIBIT 5.1 

Of 
 INCENTIVE STOCK OPTION
AGREEMENT 
 The ISO for                  shares shall be
exercisable with respect to twenty-five percent (25%) of the total number of ISO shares vest one year after the Vesting Base Date and, thereafter, with respect to an additional six and one quarter percent (6.25%) of such shares at the end
of each three-month period after the first anniversary of the Vesting Base Date, so that all of the ISO shares may be purchased on and after the fourth anniversary of the Vesting Base Date. 

Initialed by:             FIBROGEN, INC. 

 

					
	By:	 	  

		 	Thomas Neff
		
		 	Title: CEO
		
	Optionee:	 	  

			
		 	Print Name:EX-10.2(iii)

 Exhibit 10.2(iii) 

FIBROGEN, INC. 

AMENDMENT 

TO STOCK OPTION AGREEMENT 

GRANTED UNDER 1999 STOCK PLAN 

Pursuant to your Election to Participate in FibroGen’s Amendment and Exchange Offer ending on June 24, 2010 (your
“Election”), this Amendment (the “Amendment”) is entered into and made effective on June 24, 2010 (the “Amendment Effective Date”) by and between you,
[                    ] (“Optionee”) and FibroGen, Inc. and its subsidiaries (“Company”). This Amendment amends the Stock
Option Agreement that governs the option with Option Grant Number [                    ] (now referred to as
MA[        ]) granted on [                    ] for
[                ] shares of FibroGen Common Stock, for which you have agreed to amend pursuant to your executed Election (the “Option Agreement”).
Optionee and Company shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Option Agreement, together with its corresponding Option Grant Notice and this Amendment are collectively
referred to as the “Agreement”. 
 For good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Amendment shall have the meaning ascribed to them in their respective Option Agreement. 

 

	 	(2)	For the purpose of the Agreement, a “Change of Control Event” shall mean the occurrence of a single transaction or series of related transactions of any one or more of the following events:

 (i) there is consummated a merger, consolidation or similar transaction involving (directly or
indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting
securities representing more than fifty percent (50%) of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined
outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their ownership of the outstanding voting securities of the Company
immediately prior to such transaction; 
 (ii) the stockholders of the Company approve or the Board approves a plan
of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur; or 

  
 1 

 (iii) there is consummated a sale, lease, exclusive license or other
disposition of all or substantially all, as determined by the Board in its sole discretion, of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the
consolidated assets of the Company and its Subsidiaries to an Entity, more than fifty percent (50%) of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as
their ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; provided, however, that for purposes of the foregoing, in no event shall “substantially all”
mean less than fifty percent (50%) of the consolidated assets of the Company and its Subsidiaries, as determined by the Board in its sole discretion. 

The term Change of Control Event shall not include a merger or other transaction effected exclusively for the purpose of changing the domicile
of the Company. 
  

	 	(3)	Section 3 of the Option Agreement is hereby deleted in its entirety and replaced with the following: 

“The Term of your option commences on the Grant Date and expires on the day before the tenth (10th) anniversary of
the Grant Date regardless of your employment status.” 
  

	 	(4)	Section 5.3 of the Option Agreement is hereby deleted in its entirety and replaced with the following: 

“Manner of Exercise. Optionee may exercise this option, or any portion of this option, within sixty (60) days
of the expiration of its Term, as set forth in Section 3 hereof, or at any time during your Term provided that a Liquidity Event (as defined below) has occurred, by delivering a notice of exercise in a form acceptable to the Company and
executed by Optionee together with payment of the exercise price and payment of any mandatory withholding or employment taxes, as requested by the Company, to the Secretary of the Company, or to such other person as the Company may designate, during
regular business hours, together with such additional documents as the Company may then require. For the purpose of this Agreement, a “Liquidity Event” shall be defined to have occurred on either (a) the effective date of a
registration statement for an initial public offering, filed by the Company under the Securities Act; or (b) the execution of an agreement, or approval of a plan or other similar document providing for a transaction or series of transactions
that, if completed, would constitute a Change of Control Event (as defined below), provided that, in the event you deliver a Notice of Exercise prior to the completion of such Change of Control Event in satisfaction of the above requirements,
the exercise shall only be effective, if at all, upon or immediately prior to, as applicable, the completion of the transaction or 

  
 2 

 
series of transactions constituting the Change of Control Event, as necessary for you to participate therein. The Company will provide you with notice (at the last address it has on file for you)
of a Change of Control Event upon its occurrence or, if possible within 10 days or such other time as reasonably practicable prior to the completion of such event. 
  

	 	(5)	This Amendment, together with the Option Agreement, as well as the Grant Notice and Plan referenced therein, contain the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise
provided herein, the Option Agreement has not been modified or amended and remains in full force and effect. All express or implied agreements and understandings, either oral or written, heretofore made with respect to subject matter herein are
expressly superseded in this Amendment. In the case of any conflict between the terms of the Amendment, the Option Agreement, the Grant Notice and/or the Plan, the terms of this Amendment shall control. 

  
 3 

 FIBROGEN, INC. 

AMENDMENT 

TO STOCK OPTION AGREEMENTS 

THIS AMENDMENT (the “Amendment”) is entered into and made effective on
July 1, 2013 (the “Amendment Effective Date”) by and between you, (“Optionee”) and FibroGen, Inc. (“Company”). This Amendment amends your Stock Option Agreements that govern the option grants listed on
Exhibit A hereto (the “Option Agreements”). Optionee and Company shall be referred to individually herein as a “Party”, and collectively as, the “Parties”. The Option Agreements, together with its corresponding Option
Grant Notice, this Amendment, and any previous Amendments thereof, are collectively referred to as the “Agreement”. 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Amendment shall have the meaning ascribed to them in their respective Option Agreements. 

 

	 	(2)	Section 5.3 of each of the Option Agreements is hereby deleted in its entirety and replaced with the following: 

“You may exercise the vested portion of your option [(and the unvested portion of your option if permitted)] during its Term, as set
forth in Section 3 hereof, by delivering a Notice of Exercise (in a form designated by the Company) together with payment of the exercise price, pursuant to Section 5.4 hereof, to the Secretary of the Company, or to such other person as
the Company may designate, during regular business hours, together with such additional documents as the Company may then require.” 
  

	 	(3)	Section 5.4 of each of the Option Agreements is hereby deleted in its entirety and replaced with the following: 

“METHOD OF PAYMENT. Payment of the exercise price is due in full upon exercise of all
or any part of your option. You may elect to make payment of the exercise price in cash or by check or in any of the following ways, if applicable: 

(a) So long as the Company is Listed and if approved by the Company at the time your option is exercised, pursuant to a program
developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds. For purposes of this Agreement, the Company shall be deemed to be “Listed” when the Common Stock of the Company is listed on a national securities exchange or designated as a national
market security on an interdealer quotation system, if such securities exchange or interdealer quotation system has been certified in accordance with the provisions of Section 25100(o) of the California Corporate Securities Law of 1968, as
amended. 

 (b) So long as the Company is Listed or as otherwise approved by the Company at the time
your option is exercised, by Delivery of the largest whole number of shares of Common Stock already-owned by you, free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not
exceed the aggregate exercise price; provided, that any remaining balance of the aggregate exercise price not satisfied by such Delivery of whole shares shall be paid by cash or check. “Delivery” for these purposes, in the sole
discretion of the Company at the time you exercise your option, shall include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. Notwithstanding the foregoing, you may not
exercise your option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 

(c) So long as the Company is Listed or as otherwise approved by the Company at the time your option is exercised, by a “net
exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed
the aggregate exercise price; provided, that any remaining balance of the aggregate exercise price not satisfied by such holding back of whole shares shall be paid by cash or check; provided, however, shares of Common Stock will no
longer be outstanding under an Option and will not be exercisable thereafter to the extent that (i) shares are used to pay the exercise price pursuant to the “net exercise,” (ii) shares are delivered to you as a result of such
exercise, and (iii) shares are withheld to satisfy tax withholding obligations. Note that any option, or portion thereof, that is exercised through this “net exercise” method will be disqualified as an incentive stock option and
treated as a Nonstatutory Stock Option.” 
  

	 	(4)	This Amendment, together with the Option Agreements, as well as the Grant Notice and Plan referenced therein, contain the entire understanding of the Parties with respect to the subject matter hereof. Except as
otherwise provided herein, the Option Agreements has not been modified or amended and remains in full force and effect. All express or implied agreements and understandings, either oral or written, heretofore made with respect to subject matter
herein are expressly superseded in this Amendment. In the case of any conflict between the terms of the Amendment, the Option Agreements, the Grant Notice and/or the Plan, the terms of this Amendment shall control. 

 

			
	FIBROGEN, INC.
		
	By:	 	 /s/ Pat Cotroneo

		
		 	Pat Cotroneo
		 	Chief Financial Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]